Literature DB >> 7032931

Adjuvant endocrine therapy of primary operable breast cancer. Report on the Copenhagen breast cancer trials.

T Palshof, H T Mouridsen, J L Daehnfeldt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7032931

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  7 in total

1.  Adjuvant trial for stage II receptor-positive breast cancer: CMF vs. CMF + tamoxifen in a single centre.

Authors:  L Mauriac; M Durand; J Chauvergne; F Bonichon; A Avril; P Mage; M H Dilhuydy; A Le Treut; J Wafflart; D Marée
Journal:  Breast Cancer Res Treat       Date:  1988-05       Impact factor: 4.872

Review 2.  Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer.

Authors:  Christa K Baumann; Monica Castiglione-Gertsch
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control--preliminary results of a 4-arm randomised trial. The French Adjuvant Study Group.

Authors:  J P Gérard; M Héry; D Gedouin; A Monnier; M J Goudier; J P Jacquin; F Plat; E Cabarrot; D Serin; M Namer
Journal:  Drugs       Date:  1993       Impact factor: 9.546

4.  Antiestrogen treatment of postmenopausal women with primary high risk breast cancer.

Authors:  C Rose; S M Thorpe; H T Mouridsen; J A Andersen; H Brincker; K W Andersen
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

Review 5.  Chemotherapy of breast cancer.

Authors:  L S Perlow; J F Holland
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

6.  Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.

Authors:  A Nicolini; C Colombini; L Luciani; A Carpi; L Giuliani
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

7.  CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study).

Authors:  S De Placido; F Perrone; C Carlomagno; A Morabito; C Pagliarulo; R Lauria; A Marinelli; M De Laurentiis; E Varriale; G Petrella
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.